Antibody Conjugation of a Chimeric BET Degrader Enables <i>in vivo</i> ActivityThomas H. Pillow, Peter S. Dragovich, Karen E. Gascoigne et al.|ChemMedChem|2019Cited by 193
Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor EfficacyPeter S. Dragovich, Xiaoyu Zhu, Shenhua Zhang et al.|Journal of Medicinal Chemistry|2021Cited by 168
Design and linkage optimization of ursane-thalidomide-based PROTACs and identification of their targeted-degradation properties to MDM2 proteinZhiwen Qi, Chengzhang Wang, Elvira E. Shults et al.|Bioorganic Chemistry|2021Cited by 37